Treatment for 5 days of female rats with perphenazine (5 mg/kg/day) induced full lobulo—alveolar differentiation. Long-standing adrenalectomy (12 days) decreased this mammotrophic effect of perphenazine. The mechanism of this reaction was studied in male rats in order to avoid fluctuations of the prolactin content in the anterior pituitary. Adult male rats were adrenalectomized and injected s.c. after 12 days with perphenazine (10 mg/kg). Two hours later the rats were killed and pituitary and serum prolactin levels assayed by double antibody radioimmunoassay. In intact rats, perphenazine treatment enhanced serum prolactin up to 104 ± 4 (s.e.m.) ng/ml (± 350%). Adrenalectomy alone increased serum prolactin from 30± 5 to 47 ± 6 ng/ml (+56%), and augmented the perphenazine-induced release of prolactin from the pituitary into the blood from 104 ± 4 to 147 ± 10 ng/ml (+ 42%).
In chronically adrenalectomized adult female rats extremely high amounts of prolactin (+ 1617%) were detected in the serum at the end of 5 days' treatment with perphenazine (5 mg/kg/day).
These results indicate that removal of the adrenals in male and female rats does not interfere with the ability of the pituitary to secrete prolactin. Moreover, they also show that in adrenalectomized rats the impaired mammotrophic effect of perphenazine is not due to prolactin deficiency (since high serum levels of this hormone were present) but to the absence of corticosteroids at the target organ.
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 1 | 0 | 0 |
| PDF Downloads | 1 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
